PRKAG2-AS1

Homo sapiens

ASSOCIATED WITH hypertrophic cardiomyopathy 6; lethal congenital glycogen storage disease of heart; Wolff-Parkinson-White syndrome; INTERACTS WITH 17beta-estradiol; cadmium dichloride; carbamazepine

aakg-3

Caenorhabditis elegans

Predicted to enable AMP binding activity; protein kinase binding activity; and protein kinase regulator activity. Predicted to be involved in fatty acid biosynthetic process. Predicted to be located in cytoplasm and nucleus. Predicted to be part of nucleotide-activated protein kinase complex. Expressed in alimentary muscle; body wall musculature; head neurons; spermatheca; and ventral nerve cord. Human ortholog(s) of this gene implicated in Wolff-Parkinson-White syndrome; hypertrophic cardiomyopathy 6; and lethal congenital glycogen storage disease of heart. Is an ortholog of human PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1); PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2); and PRKAG3 (protein kinase AMP-activated non-catalytic subunit gamma 3).

aakg-2

Caenorhabditis elegans

Predicted to enable AMP binding activity; protein kinase binding activity; and protein kinase regulator activity. Predicted to be involved in fatty acid biosynthetic process. Predicted to be located in cytoplasm and nucleus. Predicted to be part of nucleotide-activated protein kinase complex. Human ortholog(s) of this gene implicated in Wolff-Parkinson-White syndrome; hypertrophic cardiomyopathy 6; and lethal congenital glycogen storage disease of heart. Is an ortholog of human PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1); PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2); and PRKAG3 (protein kinase AMP-activated non-catalytic subunit gamma 3).

aakg-1

Caenorhabditis elegans

Predicted to enable AMP binding activity; protein kinase binding activity; and protein kinase regulator activity. Predicted to be involved in fatty acid biosynthetic process. Predicted to be located in cytoplasm and nucleus. Predicted to be part of nucleotide-activated protein kinase complex. Human ortholog(s) of this gene implicated in Wolff-Parkinson-White syndrome; hypertrophic cardiomyopathy 6; and lethal congenital glycogen storage disease of heart. Is an ortholog of human PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1); PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2); and PRKAG3 (protein kinase AMP-activated non-catalytic subunit gamma 3).

Prkag2

Homo sapiens

AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family. Mutations in this gene have been associated with Wolff-Parkinson-White syndrome, familial hypertrophic cardiomyopathy, and glycogen storage disease of the heart. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jan 2015]

Prkag2

Rattus norvegicus

Enables AMP binding activity and protein kinase binding activity. Contributes to AMP-activated protein kinase activity. Predicted to be involved in several processes, including glycogen metabolic process; regulation of fatty acid metabolic process; and regulation of phosphate metabolic process. Part of nucleotide-activated protein kinase complex. Human ortholog(s) of this gene implicated in Wolff-Parkinson-White syndrome; glycogen storage disease; hypertrophic cardiomyopathy 6; and lethal congenital glycogen storage disease of heart. Orthologous to human PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2); PARTICIPATES IN adenosine monophosphate-activated protein kinase (AMPK) signaling pathway; hypertrophic cardiomyopathy pathway; insulin signaling pathway; INTERACTS WITH 2,2',4,4'-Tetrabromodiphenyl ether; 2,3,7,8-tetrachlorodibenzodioxine; amitrole.